Humanized collagen antibodies and related methods
    3.
    发明申请
    Humanized collagen antibodies and related methods 失效
    人源化胶原抗体及相关方法

    公开(公告)号:US20070077199A1

    公开(公告)日:2007-04-05

    申请号:US11486894

    申请日:2006-07-14

    摘要: The invention provides an antibody, or functional fragment thereof, a grafted antibody, or functional fragment thereof, comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR, where the antibody or functional fragment thereof has specific binding activity for a cryptic collagen epitope. The invention also provides methods of using an antibody having specific binding activity for a cryptic collagen epitope, including methods of inhibiting angiogenesis, tumor growth, and metastasis.

    摘要翻译: 本发明提供抗体或其功能片段,其接枝抗体或其功能片段,其包含一个或多个在重链CDR的一个或多个CDR中具有至少一个氨基酸取代的互补决定区(CDR),其中 抗体或其功能片段对隐窝胶原表位具有特异性结合活性。 本发明还提供了使用具有对神经胶原表位具有特异性结合活性的抗体的方法,包括抑制血管发生,肿瘤生长和转移的方法。

    ß binding molecules
    4.
    发明申请
    ß binding molecules 有权
    β结合分子

    公开(公告)号:US20060110388A1

    公开(公告)日:2006-05-25

    申请号:US10544050

    申请日:2004-02-06

    IPC分类号: A61K39/395 C07K16/18

    摘要: The present invention encompasses isolated antibodies, or fragments thereof, that are humanized variants of murine antibody 266 which employ complementarity determining regions derived from murine antibody 266. The variant antibodies are useful for treatment or prevention of conditions and diseases associated with Aβ, including Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy, mild cognitive impairment, and the like.

    摘要翻译: 本发明包括使用衍生自鼠抗体266的互补决定区的鼠抗体266的人源化变体的分离的抗体或其片段。变体抗体可用于治疗或预防与Aβ相关的病症和疾病,包括阿尔茨海默氏病 唐氏综合征,脑淀粉样血管病,轻度认知障碍等。

    Recombinant IL-9 antibodies and uses thereof
    5.
    发明授权
    Recombinant IL-9 antibodies and uses thereof 失效
    重组IL-9抗体及其用途

    公开(公告)号:US08481037B2

    公开(公告)日:2013-07-09

    申请号:US13007211

    申请日:2011-01-14

    IPC分类号: A61K39/395

    摘要: The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and/or ameliorating diseases and disorders associated with aberrant expression and/or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.

    摘要翻译: 本发明提供免疫特异性结合IL-9多肽的新型抗体和包含所述抗体的组合物。 本发明还提供了预防,治疗,治疗和/或改善与IL 9或IL-9受体或其亚基的异常表达和/或活性相关的疾病和病症的方法和组合物,自身免疫性疾病,炎性疾病,增殖性疾病, 以及感染,其包括施用一种或多种免疫特异性结合IL-9多肽的抗体。 本发明还包括用于诊断,监测和预测这些疾病的方法和组合物。 本发明还涉及包含免疫特异性结合IL-9多肽的抗体的制品和试剂盒。

    Aβ binding molecules
    8.
    发明授权
    Aβ binding molecules 有权
    Abeta结合分子

    公开(公告)号:US08623365B2

    公开(公告)日:2014-01-07

    申请号:US13332753

    申请日:2011-12-21

    IPC分类号: A61K39/395

    摘要: The present invention encompasses isolated antibodies, or fragments thereof, that are humanized variants of murine antibody 266 which employ complementarity determining regions derived from murine antibody 266. The variant antibodies are useful for treatment or prevention of conditions and diseases associated with Aβ, including Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy, mild cognitive impairment, and the like.

    摘要翻译: 本发明包括使用衍生自鼠抗体266的互补决定区的鼠抗体266的人源化变体的分离的抗体或其片段。变体抗体可用于治疗或预防与Aβ相关的病症和疾病,包括阿尔茨海默氏病 唐氏综合征,脑淀粉样血管病,轻度认知障碍等。